Mesenchymal Stem Cell Therapies in Osteoarthritis Management

Osteoarthritis (OA) is a chronic degenerative joint disorder characterised by progressive loss of articular cartilage, subchondral bone remodelling and low-grade synovial inflammation. Conventional interventions focus on symptom relief without addressing tissue regeneration. Mesenchymal stem cells (MSCs) have emerged as a promising therapeutic modality owing to their capacity to differentiate into chondrocytes, modulate the immune microenvironment and secrete trophic factors that support tissue repair. These multipotent progenitors can be harvested from bone marrow, adipose tissue and other sources, expanded ex vivo and delivered via intra-articular injection or scaffold-based implantation. In preclinical models, MSCs promote extracellular matrix synthesis, inhibit catabolic enzymes and attenuate synovitis. Early-phase clinical studies report improvements in pain, function and imaging biomarkers, although variability in cell dose, delivery method and outcome measures persists. Current research seeks to optimise cell source selection, enhance engraftment or harness the MSC secretome—including extracellular vesicles and exosomes—to develop reproducible, off-the-shelf therapies that restore cartilage integrity and attenuate OA progression.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Mesenchymal Stem Cell Therapies in Osteoarthritis Management publication trend

The graph below shows the total number of articles in mesenchymal stem cell therapies in osteoarthritis management across all publications each year (not limited to Nature Index journals).

Technical terms

Mesenchymal Stem Cells (MSCs): Multipotent progenitor cells capable of differentiating into bone, cartilage and fat lineages, with immunomodulatory and trophic functions.

Chondrocytes: Specialized cells responsible for the synthesis and maintenance of articular cartilage extracellular matrix, predominantly collagen II and proteoglycans.

Immunomodulatory: Ability to modulate immune cell activity, for example by secreting anti-inflammatory cytokines that shift the joint environment from degenerative to reparative.

Extracellular Vesicles (EVs): Nano-sized membrane-bound particles released by cells, including exosomes, that carry proteins, lipids and nucleic acids to mediate intercellular communication.

Paracrine signaling: Local communication mechanism whereby cells release bioactive factors that act on neighbouring cells to influence their behaviour, critical to MSC-mediated tissue repair.

References

1. Recent Updates of Diagnosis, Pathophysiology, and Treatment on Osteoarthritis of the Knee. International Journal of Molecular Sciences (2021).
2. Mesenchymal Stem Cell Therapy for Osteoarthritis: The Critical Role of the Cell Secretome. Frontiers in Bioengineering and Biotechnology (2019).
3. Bone marrow mesenchymal stem cell-derived exosomes protect cartilage damage and relieve knee osteoarthritis pain in a rat model of osteoarthritis. Stem Cell Research & Therapy (2020).